# Topas Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/topas-therapeutics

- Industry: Biotechnology
- Headquarters: Hamburg, Germany
- Website: www.topas-therapeutics.com
- Total disclosed funding: $64M
- Latest round: Series B (Jun 27, 2021)
- Investors on record: 7

## About

Topas Therapeutics GmbH is a biopharmaceutical company specializing in advanced therapeutic solutions for autoimmune diseases and allergies through innovative nanoparticle delivery systems.Founded in 2013 and headquartered in Hamburg, Germany, Topas Therapeutics GmbH develops solutions to modulate immune responses. The company has secured a Series B funding round, raising USD 18.00 mn on June 29, 2021, co-led by Boehringer Ingelheim Venture and Evotec SE, among other investors. Topas Therapeutics has successfully completed four deals to date and holds a current company valuation of USD 101.41 mn. No subsidiaries have been mentioned, and the founder's background is not specified.Topas Therapeutics focuses on innovative therapeutic solutions aimed at addressing autoimmune diseases and allergies. The company's core product offerings revolve around proprietary technology that enhances the delivery of biologic medicines, including peptides and proteins, through a unique nanoparticle platform. This platform allows for targeted therapy that aims to modulate the immune response, thereby offering potential treatments for conditions such as diabetes and multiple sclerosis. Topas Therapeutics primarily serves biopharmaceutical companies and research institutions in North America and Europe, leveraging partnerships to advance the development and commercialization of its therapies. The company's products are designed to improve patient outcomes by providing more effective and safer treatment alternatives in the growing field of immunotherapy.Topas Therapeutics generates revenue through strategic partnerships and collaborations with biopharmaceutical firms and research organizations, which include licensing agreements and co-development initiatives. These transactions are structured around the commercialization of their proprietary technology and related therapeutics, potentially involving milestone payments and royalties based on product sales. As a B2B enterprise, the company focuses on delivering its innovative solutions to its partners, which ultimately reach healthcare providers and patients. Specific pricing plans for individual products or services are designed to reflect the value provided through their advanced therapeutic offerings, which may include flagship products aimed at specific autoimmune conditions.Topas Therapeutics plans to utilize the USD 18.00 mn raised in their Series B funding to advance their clinical proof of concept in two programs and accelerate their innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases. The company is targeting expansion into new geographic regions, with specific markets in North America and Europe identified for further outreach and development initiatives. In January 2026, The Tofoo Company Limited, a portfolio company of Comitis Capital,  agreed to acquire Topas Therapeutics GmbH from Epidarex Capital, BioMed Partners, EMBL Ventures, Vesalius Biocapital, Gimv, Boehringer Ingelheim Venture, and Evotec SE. The deal is expected to be completed later this month.

## Funding rounds

- Series B, Jun 27, 2021, $18M — EMBL Ventures, Gimv, BioMed Partners, Vesalius Biocapital, Evotec SE, Boehringer Ingelheim Venture, Epidarex Capital
- Series B, Aug 31, 2020, $26M — BioMed Partners, Vesalius Biocapital, Evotec SE, Epidarex Capital
- Series A, Nov 2, 2017, $4.7M — Boehringer Ingelheim Venture
- Series A, Mar 22, 2016, $16M — EMBL Ventures, Gimv, Evotec SE, Epidarex Capital

## Investors

- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B
- Evotec SE — Series A, Series B
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A, Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B